Not specified
The FDA's acceptance of NDA220482 for review signifies a critical step for HAISCO Pharmaceutical towards market entry. This development necessitates vigilance from competitors to assess potential impacts on their market positioning and strategies.
Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.
Last run 7/21/2026, 6:34:25 PM
Assessment confidence: 62% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.
The FDA's acceptance of NDA220482 for review signifies a critical step for HAISCO Pharmaceutical towards market entry. This development necessitates vigilance from competitors to assess potential impacts on their market positioning and strategies. Regulatory context from FDA (FDA TA — ANDA219207) supports the near-term read. Assessment grounded in 13 ranked evidence items (5 high-relevance).
Portfolio teams should assess the potential market impact of HAISCO's product and prepare for competitive responses. The strongest clinical anchor is A Study to Learn About Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease (ClinicalTrials.gov), sponsor/company relevance (pfizer). In Not specified, 3 regulatory and 2 competitive items passed relevance filtering for HAISCO Pharmaceutical.
The most relevant competitive pressure comes from FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment. This acceptance indicates HAISCO is advancing its product towards potential market entry, which could impact competitors in the same therapeutic area.
Regulatory risk is concentrated around FDA TA — ANDA219207 (FDA). Regulatory pathway relevance (nda). The acceptance of the NDA indicates that HAISCO's product is under evaluation, which could lead to approval and subsequent market competition.
Unique Pharmaceutical Laboratories (A Div.
FDAhigh relevance
Moderate corpus alignment
FDA document
View sourceReport on the State of Pharmaceutical Quality
FDAmedium relevance
Moderate corpus alignment
FDA document
View sourceA Study to Learn About Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View sourceCharacterization of Phenotypic and Genotypic Regressors for Imaging
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceHydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceCharacterization of Nociception Phenotype in Individuals With Intellectual Disability
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceTesting the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceFDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Insect-based models in pharmaceutical ecotoxicology: a bibliometric and narrative review.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceNext-generation vaccine adjuvants: Integrating nanotechnology, systems immunology, and computational approaches for precision vaccinology.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceNanomaterial-based vaccines: An advanced approach against rotavirus: A review article.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourcePrecedents · guidance
Loading regulatory precedents…
View full regulatory analysisCompetitors · threats
Loading competitive findings…
View full competitive analysisThe FDA's acceptance of NDA220482 for review signifies a critical step for HAISCO Pharmaceutical towards market entry. This development necessitates vigilance from competitors to assess potential impacts on their market positioning and strategies.
HAISCO's potential entry into the market could disrupt existing competitors, affecting their market share and revenue projections.
The acceptance of the NDA indicates that HAISCO's product is under evaluation, which could lead to approval and subsequent market competition.
Monitor the review timeline and any subsequent announcements regarding approval status or additional data requirements.
Track for follow-up milestones; no immediate action required.